Candel Therapeutics (CADL) Competitors $5.04 +0.91 (+22.03%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CADL vs. LIFE, ALGS, URGN, DRRX, ABUS, PHAT, ANAB, EXAI, DNTH, and IMNMShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include aTyr Pharma (LIFE), Aligos Therapeutics (ALGS), UroGen Pharma (URGN), DURECT (DRRX), Arbutus Biopharma (ABUS), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Exscientia (EXAI), Dianthus Therapeutics (DNTH), and Immunome (IMNM). These companies are all part of the "medical" sector. Candel Therapeutics vs. aTyr Pharma Aligos Therapeutics UroGen Pharma DURECT Arbutus Biopharma Phathom Pharmaceuticals AnaptysBio Exscientia Dianthus Therapeutics Immunome Candel Therapeutics (NASDAQ:CADL) and aTyr Pharma (NASDAQ:LIFE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate CADL or LIFE? Candel Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 118.25%. aTyr Pharma has a consensus price target of $25.50, indicating a potential upside of 0.00%. Given Candel Therapeutics' higher possible upside, equities research analysts clearly believe Candel Therapeutics is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in CADL or LIFE? 13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer CADL or LIFE? aTyr Pharma received 413 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 59.69% of users gave aTyr Pharma an outperform vote while only 52.94% of users gave Candel Therapeutics an outperform vote. CompanyUnderperformOutperformCandel TherapeuticsOutperform Votes952.94% Underperform Votes847.06% aTyr PharmaOutperform Votes42259.69% Underperform Votes28540.31% Which has more risk and volatility, CADL or LIFE? Candel Therapeutics has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Which has better earnings & valuation, CADL or LIFE? Candel Therapeutics has higher earnings, but lower revenue than aTyr Pharma. Candel Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K1,364.16-$37.94M-$1.73-2.91aTyr Pharma$350K0.00-$50.39M-$0.90N/A Is CADL or LIFE more profitable? aTyr Pharma's return on equity of -56.92% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -629.29% -173.39% aTyr Pharma N/A -56.92%-43.87% Does the media prefer CADL or LIFE? In the previous week, Candel Therapeutics had 14 more articles in the media than aTyr Pharma. MarketBeat recorded 17 mentions for Candel Therapeutics and 3 mentions for aTyr Pharma. Candel Therapeutics' average media sentiment score of 0.37 beat aTyr Pharma's score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryaTyr Pharma beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.70M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E Ratio-2.9144.06102.4617.58Price / Sales1,364.16392.921,234.85158.43Price / CashN/A169.3840.4736.33Price / Book-10.724.597.096.50Net Income-$37.94M-$41.63M$119.65M$226.22M7 Day Performance32.63%2.61%2.06%3.76%1 Month Performance-11.58%-2.47%-2.46%4.63%1 Year Performance460.00%28.24%33.95%29.20% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.3849 of 5 stars$5.04+22.0%$11.00+118.3%+460.0%$163.70M$120,000.00-2.9160Analyst RevisionLIFEaTyr Pharma1.5491 of 5 starsN/A$25.50+∞N/A$131.12M$350,000.00-2.1156Analyst ForecastALGSAligos Therapeutics3.8379 of 5 stars$18.95-4.2%$75.00+295.8%+17.9%$68.03M$15.53M-1.4890URGNUroGen Pharma3.743 of 5 stars$11.94+3.4%$48.38+305.2%-4.9%$280.04M$89.36M-3.69200DRRXDURECT3.0924 of 5 stars$0.94+8.9%$5.00+432.0%+55.4%$29.17M$8.55M-1.5680Analyst ForecastGap UpABUSArbutus Biopharma2.6471 of 5 stars$3.51+1.4%$5.50+56.7%+90.8%$665.12M$6.74M-8.1273Analyst ForecastPHATPhathom Pharmaceuticals2.628 of 5 stars$9.71+2.8%$22.50+131.7%+33.6%$663.97M$680,000.00-1.68110ANABAnaptysBio2.5319 of 5 stars$21.65+2.3%$54.64+152.4%+56.8%$658.79M$57.17M-3.49100EXAIExscientia2.2455 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M-3.21280News CoverageDNTHDianthus Therapeutics1.3492 of 5 stars$21.32+5.2%$46.43+117.8%+96.7%$631.01M$5.37M-8.5680IMNMImmunome1.86 of 5 stars$9.93+5.4%$28.83+190.4%+23.7%$619.83M$14.02M-1.1740 Related Companies and Tools Related Companies LIFE Competitors ALGS Competitors URGN Competitors DRRX Competitors ABUS Competitors PHAT Competitors ANAB Competitors EXAI Competitors DNTH Competitors IMNM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CADL) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
